IFNG and ovarian carcinoma: Travers et al. found that DNMTi 5-azacytidine (5AZA-C) activated type I interferon signaling in ovarian cancer, catalyzed the number of IFN-γ+ immune cells and lowered the percentage of macrophages in TME [165].